AltheaDx News

AltheaDx announces appointment of new CEO and President and adds Dr. Ann Kessler to the Board of Directors

San Diego, CA, April 28, 2010 – AltheaDx, Inc., a privately held molecular diagnostics company and a leader in the development of companion diagnostics for biopharmaceutical partners, today announced that Wendy Benson has been appointed CEO and President, replacing interim co-CEOs, Drs. François Ferré and Magda Marquet.  Additionally, the company announced the appointment of Dr. Ann Kessler and Wendy Benson to the AltheaDx Board of Directors. [More]

AltheaDx and The Nicholas Conor Institute for Pediatric Cancer Research Announce Molecular Diagnostics Collaboration to Improve the Diagnosis and Treatment of Childhood Cancer

SAN DIEGO, April 18, 2010--AltheaDx, Inc., a leader in the development of companion diagnostics, and The Nicholas Conor Institute for Pediatric Cancer Research, announced today that they have entered into collaboration to: develop a broad panel of diagnostic, prognostic, and treatment prediction information for pediatric cancer, provide actionable information to attending physicians that will best guide treatment for pediatric cancer, and achieve a significant milestone towards The Nicholas Conor Institute’s mission of improving diagnosis and treatment of pediatric cancer. [More]

AltheaDx Closes Series A Financing To Support Development of Companion Molecular Diagnostics

San Diego, CA, March 10, 2010 – AltheaDx, Inc., a privately held molecular diagnostics company and a leader in the development of companion diagnostics for biopharmaceutical partners, announced that it has completed a $6 million Series A equity and growth financing. [More]

AltheaDx Receives CLIA Certification

Expanding their service offering with clinical laboratory testing. [More]

Eric Topol Appointed to the AltheaDx Scientific Advisory Board

Key appointment of a leader in translational medicine - Eric J. Topol, M.D. [More]

Greg Tsongalis Appointed to the AltheaDx Scientific Advisory Board

Key appointment of a well respected clinician Gregory J. Tsongalis, Ph.D., HCLD, FACB. [More]

AltheaDx Forms Scientific Advisory Board

Key appointments include Doctors and Researchers from Industry and Academia. [More]

AltheaDx Expands Genotyping Menu for Drug Metabolism

New microarray offering expands existing capabilities with Affymetrix' Drug Metabolizing Enzymes and Transporters (DMET Plus) for comprehensive genetic studies of pharmacokinetics [More]

Clinical Researchers Get New Tool to Ensure Accuracy of Genetic Testing

AltheaDx launches world’s first assay to test quality of RNA isolated from FFPE specimens [More]

AltheaDx to Offer the DxS K-RAS Test for Clinical Studies

DxS K-RAS test will assist US oncologists in studying patient response to cancer therapies in clinical trials [More]

AltheaDx Appoints Vice President of Business Development, Sales and Marketing

AltheaDx Appoints Cyrus Mirsaidi Vice President of Business Development, Sales and Marketing [More]

AltheaDx Named Affymetrix Authorized Service Provider

AltheaDx Will Offer Affymetrix Technology as Part of a Complete Biomarker Discovery and Development Platform [More]

Poniard Pharmaceuticals and AltheaDx Sign Agreement

Poniard to investigate molecular signatures for platinum resistance [More]

AltheaDx Board of Directors Appoints Industry Veteran CEO

AltheaDx announced today that David Macdonald has been appointed the Chief Executive Officer of the firm. [More]

Althea Technologies Announces the Spin-out of an Independent Company, AltheaDx

Independent company to commercialize its breakthrough genetic testing technology through a variety of laboratory services and gene expression products for use in monitoring and managing cancer treatment. [More]

Althea Technologies Expands Collaboration with BiPar Sciences

Expansion of a collaboration with BiPar Sciences, Inc. to provide pharmacogenomic support for BiPar’s drug development programs in oncology. [More]

Althea Technologies Announces the Development of a Diagnostic Capable of Differentiating Multiple Forms of Childhood Cancer

Development of a diagnostic resulting from collaborative efforts between Althea and the U.S. National Cancer Institute (NCI). [More]

Althea Technologies and Blueshift Biotechnologies Combine Technologies for High Throughput, Gene Expression Screening

Althea has received a SBIR award from the National Human Genome Research Institute to explore the potential for practical high throughput and low cost gene expression analysis. [More]

Althea Introduces Time Saving Assay For Predicting Carcinogenicity Using Pcr-Based Gene Expression Profiling

Introduction of an novel lead compound toxicity classification assay employing multiplex gene expression screening paired with neural network analysis. [More]

Althea Presents Application Of Gene Expression Technology For Cancer Diagnostics At The American Society Of Clinical Oncology Meeting

Althea's multiplexed PCR technology for quantitative gene expression in cancer diagnosis will be presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) [More]

Althea Launches Glp Clinical Gene Expression Services Using Beckman Coulter’s Gexp Quantitative Multiplexed PCR System

Introduction of Good Laboratory Practices (GLP) compliant testing services for routine gene expression analysis of clinical samples. [More]

Althea Awarded NCI Grant To Apply Innovative Technology In Compound Library Expression Screening

Grant to develop and demonstrate the value of screening compound libraries using Althea's eXpress Profiling™ high-throughput gene expression screen. [More]

Althea Awarded Technology Grant

Althea receives Phase I Small Business Innovation Research grant from the National Institutes of Health [More]

Natural Selection and Althea Technologies in Strategic Alliance to Provide Gene Expression Biomarker Discovery

Comprehensive set of services will allow researchers to progress from global to focused gene expression analysis [More]

Althea Awarded NCI Grant To Apply Innovative Technology In Diagnosis Of Childhood Cancers

Phase I SBIR grant received from the National Cancer Institute (NCI) [More]

Althea Awarded Innovative Toxicology Grant From NIH

Phase I SBIR grant received from the Innovative Toxicology Models Program of the National Institutes of Health [More]

Beckman Coulter Signs Agreement With Althea Technologies For Gene Expression Technology

Beckman Coulter plans to integrate eXpress Profiling into its GenomeLab suite of genetic analysis solutions to speed drug discovery. [More]

Althea Announces Issuance Of U.S. Patent For High Throughput Gene Expression Analysis

Althea granted U.S. Patent number 6,618,679 covering its eXpress Profiling™ technology. [More]

Althea Presents Multiplex Pcr Data Related To Toxicogenomics

Althea's quantitative, multiplex PCR technology, eXpress Profiling™, can successfully monitor the impact of compounds on the expression of selected genes for early toxicological screening in a high-throughput format. [More]

Althea’s Express Profiling Technology Used In High-Throughput Multiplexed Gene Expression Study

Results of a pioneering study using multiplexed gene expression in compound library screening published in the Molecular Cancer Therapeutics. [More]

Althea Technologies, Inc. Offers Full Scope Custom Integration Study Assays For DNA Vaccines

Studies include a complex protocol of procedures designed to separate high molecular weight DNA from low molecular weight plasmid-derived DNA [More]